Vir Biotechnology (NASDAQ:VIR) Stock: Insider Verneuil Vanina De Sells 2,407 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 2,407 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the transaction, the executive vice president directly owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. This trade represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, November 2nd, Vanina de Verneuil sold 1,343 shares of Vir Biotechnology stock. The shares were sold at an average price of $11.33, for a total transaction of $15,216.19.

Vir Biotechnology Stock Down 6.4%

Shares of NASDAQ VIR opened at $11.02 on Friday. The firm’s 50-day moving average price is $11.01 and its 200-day moving average price is $9.58. The company has a market cap of $1.86 billion, a PE ratio of -8.75 and a beta of 1.70. Vir Biotechnology, Inc. has a 52-week low of $4.82 and a 52-week high of $12.19.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.98 million. The firm’s revenue for the quarter was down 178.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.17) earnings per share. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd. Raymond James Financial reissued a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. HC Wainwright raised their target price on Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Finally, Zacks Research downgraded Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.14.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently bought and sold shares of VIR. BlackRock Inc. purchased a new position in shares of Vir Biotechnology in the second quarter valued at about $210,712,000. ARCH Venture Management LLC bought a new position in shares of Vir Biotechnology in the second quarter worth about $129,353,521. ADAR1 Capital Management LLC purchased a new stake in shares of Vir Biotechnology during the first quarter worth about $24,593,000. Dimensional Fund Advisors LP raised its stake in Vir Biotechnology by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company’s stock valued at $23,107,000 after purchasing an additional 43,401 shares during the period. Finally, Bank of America Corp DE bought a new stake in Vir Biotechnology during the 2nd quarter valued at approximately $11,642,000. Institutional investors own 65.32% of the company’s stock.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Needham raised its price target to $20 from $18 and maintained a Buy rating, signaling a more bullish analyst view. Needham rating details
• Positive Sentiment: Vir said it expects to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart at AASLD’s 2026 liver meeting. The data could be an important catalyst for the company’s hepatitis delta program. AASLD presentation announcement
• Neutral Sentiment: Management expects its cash runway to extend into the second half of 2028, helping fund development, while the timing and outcome of upcoming clinical catalysts remain uncertain. Cash runway and trial timing
• Neutral Sentiment: An executive’s small stock sale was made under a pre-arranged plan to cover tax withholding on vested equity awards, making it a limited signal about the company’s outlook. Insider transaction details
• Negative Sentiment: Third-quarter revenue was negative $0.19 million, below the roughly $0.98 million expected and down 178.3% year over year. Although the loss of $0.57 per share was narrower than analysts’ estimates, the revenue miss may be overshadowing that earnings beat. Q3 results and corporate update

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.